Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Long-Term Efficacy of Rehabilitation Following Arthroscopic Synovectomy in Patients With Rheumatoid Arthritis Treated With Biologic Agents.

Kanbe K, Sekine C.

Ann Rehabil Med. 2017 Dec;41(6):998-1004. doi: 10.5535/arm.2017.41.6.998. Epub 2017 Dec 28.

2.

Adaptation and Validation of the Foot Function Index-Revised Short Form into Polish.

Rutkowski R, Gałczyńska-Rusin M, Gizińska M, Straburzyński-Lupa M, Zdanowska A, Romanowski MW, Romanowski W, Budiman-Mak E, Straburzyńska-Lupa A.

Biomed Res Int. 2017;2017:6051698. doi: 10.1155/2017/6051698. Epub 2017 Nov 27.

4.

Physical activity and sedentary behavior in patients with systemic lupus erythematosus and rheumatoid arthritis.

Legge A, Blanchard C, Hanly JG.

Open Access Rheumatol. 2017 Nov 8;9:191-200. doi: 10.2147/OARRR.S148376. eCollection 2017.

5.

Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment.

Schiff M, Takeuchi T, Fleischmann R, Gaich CL, DeLozier AM, Schlichting D, Kuo WL, Won JE, Carmack T, Rooney T, Durez P, Shaikh S, Hidalgo RP, van Vollenhoven R, Zerbini CAF.

Arthritis Res Ther. 2017 Sep 18;19(1):208. doi: 10.1186/s13075-017-1410-1.

6.

Facilitated access to an integrated model of care for arthritis in an urban Aboriginal population.

Barnabe C, Lockerbie S, Erasmus E, Crowshoe L.

Can Fam Physician. 2017 Sep;63(9):699-706.

7.

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.

Keystone EC, Taylor PC, Tanaka Y, Gaich C, DeLozier AM, Dudek A, Zamora JV, Cobos JAC, Rooney T, Bono S, Arora V, Linetzky B, Weinblatt ME.

Ann Rheum Dis. 2017 Nov;76(11):1853-1861. doi: 10.1136/annrheumdis-2017-211259. Epub 2017 Aug 10.

8.

Skeletal Muscle Fat and Its Association With Physical Function in Rheumatoid Arthritis.

Khoja SS, Moore CG, Goodpaster BH, Delitto A, Piva SR.

Arthritis Care Res (Hoboken). 2017 May 8. doi: 10.1002/acr.23278. [Epub ahead of print]

PMID:
28482146
9.

Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis.

Emery P, Blanco R, Maldonado Cocco J, Chen YC, Gaich CL, DeLozier AM, de Bono S, Liu J, Rooney T, Chang CH, Dougados M.

RMD Open. 2017 Mar 21;3(1):e000410. doi: 10.1136/rmdopen-2016-000410. eCollection 2017.

10.

Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study.

Van den Bosch F, Ostor AJK, Wassenberg S, Chen N, Wang C, Garg V, Kalabic J.

Rheumatol Ther. 2017 Jun;4(1):85-96. doi: 10.1007/s40744-017-0061-7. Epub 2017 Mar 30. Erratum in: Rheumatol Ther. 2017 Jun;4(1):97.

11.

Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis.

Kihara M, Davies R, Kearsley-Fleet L, Watson KD, Lunt M, Symmons DP, Hyrich KL; British Society for Rheumatology Biologics Register.

Clin Rheumatol. 2017 Feb;36(2):241-250. doi: 10.1007/s10067-016-3485-5. Epub 2016 Dec 2.

12.

Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).

Smolen JS, Kremer JM, Gaich CL, DeLozier AM, Schlichting DE, Xie L, Stoykov I, Rooney T, Bird P, Sánchez Bursón JM, Genovese MC, Combe B.

Ann Rheum Dis. 2017 Apr;76(4):694-700. doi: 10.1136/annrheumdis-2016-209821. Epub 2016 Oct 31.

13.
14.

Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials.

Wolters PL, Martin S, Merker VL, Tonsgard JH, Solomon SE, Baldwin A, Bergner AL, Walsh K, Thompson HL, Gardner KL, Hingtgen CM, Schorry E, Dudley WN, Franklin B; REiNS International Collaboration.

Neurology. 2016 Aug 16;87(7 Suppl 1):S4-S12. doi: 10.1212/WNL.0000000000002927.

15.

Pain mechanisms and ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: protocol for a prospective, exploratory cohort study.

Højgaard P, Christensen R, Dreyer L, Mease P, de Wit M, Skov L, Glintborg B, Christensen AW, Ballegaard C, Bliddal H, Bukhave K, Bartels EM, Amris K, Ellegaard K, Kristensen LE.

BMJ Open. 2016 Apr 15;6(4):e010650. doi: 10.1136/bmjopen-2015-010650.

16.
17.

Initial combination therapy versus step-up therapy in treatment to the target of remission in daily clinical practice in early rheumatoid arthritis patients: results from the DREAM registry.

Steunebrink LM, Versteeg GA, Vonkeman HE, Ten Klooster PM, Kuper HH, Zijlstra TR, van Riel PL, van de Laar MA.

Arthritis Res Ther. 2016 Mar 8;18:60. doi: 10.1186/s13075-016-0962-9.

18.

Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry.

Steunebrink LM, Vonkeman HE, ten Klooster PM, Hoekstra M, van Riel PL, van de Laar MA.

Clin Rheumatol. 2016 Mar;35(3):609-15. doi: 10.1007/s10067-016-3191-3. Epub 2016 Feb 6.

19.

Predicting and verifying outcome of Tripterygium wilfordii Hook F. based therapy in rheumatoid arthritis: from open to double-blinded randomized trial.

Jiang M, Zha Q, Zhang C, Lu C, Yan X, Zhu W, Liu W, Tu S, Hou L, Wang C, Zhang W, Liang Q, Fan B, Yu J, Zhang W, Liu X, Yang J, He X, Li L, Niu X, Liu Y, Guo H, He B, Zhang G, Bian Z, Lu A.

Sci Rep. 2015 Apr 15;5:9700. doi: 10.1038/srep09700.

20.

Comparison of the Belgian Rheumatoid Arthritis Disability Assessment and Health Assessment Questionnaires as Tools to Predict the Need for Support Measures in Patients with Rheumatoid Arthritis.

Janssens X, Decuman S, De Keyser F; Belgian Rheumatoid Arthritis Disability Assessment study group.

PLoS One. 2016 Jan 22;11(1):e0146688. doi: 10.1371/journal.pone.0146688. eCollection 2016.

Supplemental Content

Support Center